Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2016

01.12.2016 | short review

Post ASCO update 2016—lung cancer

verfasst von: Georg Pall, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Summary

The aim of this short review is to summarize the most important data relating to the field of thoracic tumors presented at the 2016 ASCO annual meeting. For small cell lung cancer (SCLC) the treatment algorithms once again remain unchanged. The CONVERT study was not able to show superiority of a modern chemoradiotherapy regimen using once daily fractionation over the historical standard of hyperfractionated chemoradiotherapy. With rovalpituzumab tesirine a promising new agent is in development, leading to encouraging treatment results in patients with pretreated, extensive SCLC disease on phase IB level. Regarding nonsmall cell lung cancer (NSCLC) a phase II trial was able to confirm high efficacy of the combination dabrafenib/trametinib if a BRAF-V600E mutation is detectable. These data should lead to more widespread implementation of BRAF mutation testing in routine diagnostic work-up. In the J‑ALEX trial alectinib outperformed crizotinib in the first-line treatment of Asian patients with ALK-rearranged metastatic NSCLC. However, further data from ongoing studies will be necessary to better define the optimal sequencing of treatments for this genetically defined subgroup of patients.
Literatur
1.
Zurück zum Zitat Turrisi ET, Kyungmann K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and eoposide. New Engl J Med. 1999;340(4):265–71.CrossRef Turrisi ET, Kyungmann K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and eoposide. New Engl J Med. 1999;340(4):265–71.CrossRef
2.
Zurück zum Zitat Komaki R, Khalid N, Langer CJ, et al. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys. 2013;85(4):1066–73.CrossRef Komaki R, Khalid N, Langer CJ, et al. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys. 2013;85(4):1066–73.CrossRef
3.
Zurück zum Zitat Faivre-Finn C, Snee M, Ashcroft L, et al. CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). J Clin Oncol. 2016;34(suppl):abstr 8504.CrossRef Faivre-Finn C, Snee M, Ashcroft L, et al. CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). J Clin Oncol. 2016;34(suppl):abstr 8504.CrossRef
5.
Zurück zum Zitat Rudin CM, Pietanza MC, Bauer TM, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol. 2016;34(suppl):abstr LBA8505.CrossRef Rudin CM, Pietanza MC, Bauer TM, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol. 2016;34(suppl):abstr LBA8505.CrossRef
6.
Zurück zum Zitat Antonia SJ, Lopez-Martin JA, Bendell JC, et al. Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). J Clin Oncol. 2016;34(suppl):abstr 100.CrossRef Antonia SJ, Lopez-Martin JA, Bendell JC, et al. Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). J Clin Oncol. 2016;34(suppl):abstr 100.CrossRef
7.
Zurück zum Zitat Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.CrossRef Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.CrossRef
8.
Zurück zum Zitat Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015;121(3):448–56.CrossRef Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015;121(3):448–56.CrossRef
9.
Zurück zum Zitat Planchard D, Kim T, Mazieres J, et al. Dabrafenib in patients with BRAF (V600E)-positive advanced non-small-cell lung cancer : a single-arm, multicenter, open-label, phase II trial. Lancet Oncol. 2016;17(5):642–50.CrossRef Planchard D, Kim T, Mazieres J, et al. Dabrafenib in patients with BRAF (V600E)-positive advanced non-small-cell lung cancer : a single-arm, multicenter, open-label, phase II trial. Lancet Oncol. 2016;17(5):642–50.CrossRef
10.
Zurück zum Zitat Gautschi O, Milia J, Cabarrou B, et al. Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF cohort. J Thorac Oncology. 2015;10(10):1451–7.CrossRef Gautschi O, Milia J, Cabarrou B, et al. Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF cohort. J Thorac Oncology. 2015;10(10):1451–7.CrossRef
11.
Zurück zum Zitat Long GV, Stoyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicenter, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51.CrossRef Long GV, Stoyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicenter, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51.CrossRef
12.
Zurück zum Zitat Planchard D, Besse B, Groen HJM, et al. An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928). J Clin Oncol. 2016;34(suppl):abstr 107.CrossRef Planchard D, Besse B, Groen HJM, et al. An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928). J Clin Oncol. 2016;34(suppl):abstr 107.CrossRef
13.
Zurück zum Zitat Solomon BJ, Mok T, Dong-Wan K, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med. 2014;371(23):2167–77.CrossRef Solomon BJ, Mok T, Dong-Wan K, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med. 2014;371(23):2167–77.CrossRef
14.
Zurück zum Zitat Nokihara H, Hida T, Kondo M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+NSCLC): Primary resultsfrom the J‑ALEX study. J Clin Oncol. 2016;34(suppl):abstr 9008.CrossRef Nokihara H, Hida T, Kondo M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+NSCLC): Primary resultsfrom the J‑ALEX study. J Clin Oncol. 2016;34(suppl):abstr 9008.CrossRef
15.
Zurück zum Zitat Solomon BJ, Bauer TM, Felip E, et al. Safety and efficacy of lorlatinib (PF-06463922) form the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cel lung cancer (NSCLC). J Clin Oncol. 2016;34(suppl):abstr 9009.CrossRef Solomon BJ, Bauer TM, Felip E, et al. Safety and efficacy of lorlatinib (PF-06463922) form the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cel lung cancer (NSCLC). J Clin Oncol. 2016;34(suppl):abstr 9009.CrossRef
16.
Zurück zum Zitat Hellmann MD, Gettinger SN, Goldman JW, et al. CheckMate 012: Safety and efficacy of first-line (FL) nivolumab (nivo;N) and ipilimumab (ipi;I) in advanced (adv) NSCLC. J Clin Oncol. 2016;34(suppl):abstr 3001.CrossRef Hellmann MD, Gettinger SN, Goldman JW, et al. CheckMate 012: Safety and efficacy of first-line (FL) nivolumab (nivo;N) and ipilimumab (ipi;I) in advanced (adv) NSCLC. J Clin Oncol. 2016;34(suppl):abstr 3001.CrossRef
17.
Zurück zum Zitat Kindler HL, Scherpereel A, Calabro L, et al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, placebo-controlled, double blind phase III DETERMINE study. J Clin Oncol. 2016;34(suppl):abstr 8502.CrossRef Kindler HL, Scherpereel A, Calabro L, et al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, placebo-controlled, double blind phase III DETERMINE study. J Clin Oncol. 2016;34(suppl):abstr 8502.CrossRef
18.
Zurück zum Zitat Giaccone G, Thompson J, Crawford J, et al. A phase II study of pembrolizumab for patients with recurrent thymic carcinoma. J Clin Oncol. 2016;34(suppl):abstr 8517.CrossRef Giaccone G, Thompson J, Crawford J, et al. A phase II study of pembrolizumab for patients with recurrent thymic carcinoma. J Clin Oncol. 2016;34(suppl):abstr 8517.CrossRef
Metadaten
Titel
Post ASCO update 2016—lung cancer
verfasst von
Georg Pall, MD
Publikationsdatum
01.12.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0302-4

Weitere Artikel der Ausgabe 4/2016

memo - Magazine of European Medical Oncology 4/2016 Zur Ausgabe